Browse the latest research summaries in the field of pain management for spinal cord injury patients and caregivers.
Showing 11-20 of 682 results
Neural Regeneration Research, 2014 • May 1, 2014
This study investigated the analgesic effect of bumetanide, a specific sodium-potassium-chloride co-transporter 1 (NKCC1) inhibitor, and the change in spinal NKCC1 and potassium-chloride co-transporte...
KEY FINDING: Intrathecal bumetanide could decrease cumulative pain scores, and could increase thermal and mechanical pain thresholds in a rat model of incisional pain.
Neural Regen Res, 2012 • May 1, 2012
This study aimed to verify if rat spinal cord prokineticin 1 and its receptor contribute to the analgesic effect of suspended moxibustion in a rat model of irritable bowel syndrome where rats display ...
KEY FINDING: Suspended moxibustion at Tianshu (ST25) significantly decreased visceral sensitivity to colorectal distention in rats with CVH.
Annals of Medicine, 2024 • April 16, 2024
Complex regional pain syndrome (CRPS) is a debilitating and complex condition that places a significant physical, psychological and emotional burden upon afflicted patients necessitating multi-modal a...
KEY FINDING: CRPS can be classified into two main categories: type 1 and type 2, with type 2 resulting from nerve damage.
Journal of Neurochemistry, 2025 • August 4, 2024
Myelination, carried out by oligodendrocytes in the CNS, is critical for the efficient transmission of neural information. This review elucidates how the death of oligodendrocytes, demyelination, and ...
KEY FINDING: Oligodendrocyte loss or dysfunction contributes to neuropathic pain following peripheral nerve injury, spinal cord injury, chemotherapy, and HIV infection.
BRAIN, 2025 • August 21, 2024
This study investigates the role of spinal mTORC2 in inflammatory and neuropathic pain. Activation of mTORC2 induces pain hypersensitivity, while inhibition alleviates both types of pain. Cell type-sp...
KEY FINDING: Pharmacological activation of spinal mTORC2 induces pain hypersensitivity.
IBRO Neuroscience Reports, 2024 • September 5, 2024
The study aimed to explore the potential therapeutic effects of irisin on chronic neuralgia and related affective disorders in a CCI mice model. The results indicated that irisin treatment could allev...
KEY FINDING: Irisin treatment ameliorated CCI-induced mechanical allodynia, thermal hyperalgesia, depressive, and anxiety behaviors in mice.
PAIN Reports, 2024 • November 6, 2024
This study investigates the role of spinal HDACs in chronic constriction injury (CCI)-induced neuropathic pain in rats, focusing on the GABA system. The results demonstrate that CCI upregulates HDAC3,...
KEY FINDING: Spinal hdac3, hdac4, and hdac6 were upregulated in CCI rats, indicating their potential role in neuropathic pain.
Cellular and Molecular Neurobiology, 2024 • November 28, 2024
Neuropathic pain after SCI is caused by glial cells, ectopic firing of neurons endings and their intra- and extracellular signaling mechanisms. SCI causes activation of astrocytes and microglia across...
KEY FINDING: Activated astrocytes and microglia are essential for the development and maintenance of SCI-NP.
Journal of Central Nervous System Disease, 2024 • January 1, 2024
This study demonstrates the surgical procedure and clinical significance of percutaneous endoscope-assisted CL implantation for SCS in managing neuropathic pain. The endoscopic-assisted technique allo...
KEY FINDING: Successful cylindrical lead implantation under endoscopic guidance was achieved in all patients, including those with failed back surgery syndrome, complex regional pain syndrome, and chronic pelvic pain.
J Clin Invest, 2025 • December 10, 2024
The study identifies C2230 as a state- and use-dependent CaV2.2 channel blocker, meaning it preferentially inhibits channels that are frequently activated or in an inactivated state. C2230 was shown t...
KEY FINDING: C2230 inhibits CaV2.2 channels in rat, marmoset, and human neurons in a G-protein-coupled-receptor–independent manner.